Stockscreener 앱 받기
15.39
3.69%
-0.59
시장 영업 전:
15.39
전일 마감가:
$15.98
열려 있는:
$15.9
하루 거래량:
86,878
Relative Volume:
0.81
시가총액:
$318.68M
수익:
$306.91M
순이익/손실:
$-59.11M
주가수익비율:
-102.60
EPS:
-0.15
순현금흐름:
$6.35M
1주 성능:
-4.82%
1개월 성능:
+0.03%
6개월 성능:
+33.09%
1년 성능:
+22.41%
1일 변동 폭
$15.30
$16.00
1주일 범위
$15.30
$16.17
52주 변동 폭
$7.08
$17.49
Amarin Corp Adr Stock (AMRN) Company Profile
명칭
Amarin Corp Adr
전화
353 1 6699 020
주소
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
AMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
15.39 | 334.44M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
695.59 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.41 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
207.47 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.99 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
85.33 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-10-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-05-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-05-05 | 개시 | Northland Capital | Outperform |
| 2020-03-31 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-31 | 업그레이드 | Oppenheimer | Underperform → Perform |
| 2020-03-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-02 | 개시 | Cowen | Outperform |
| 2020-02-18 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-01-06 | 개시 | JP Morgan | Neutral |
| 2019-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-20 | 개시 | Oppenheimer | Underperform |
| 2019-11-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-11-15 | 재확인 | SVB Leerink | Outperform |
| 2019-10-31 | 개시 | Aegis Capital | Buy |
| 2019-10-15 | 개시 | Goldman | Neutral |
| 2019-08-14 | 개시 | SVB Leerink | Outperform |
| 2019-07-09 | 재확인 | Jefferies | Buy |
| 2019-06-17 | 개시 | ROTH Capital | Buy |
| 2019-03-22 | 개시 | Stifel | Buy |
모두보기
Amarin Corp Adr 주식(AMRN)의 최신 뉴스
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin licenses VAZKEPA to Recordati in 59 European countries - Investing.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - Barchart.com
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Looking For A Top Momentum Stock? Check Out Amarin Corp ADR (NASDAQ: AMRN) - Stocksregister
Amarin Takes Critical Step to Avoid Nasdaq Delisting with 1-for-20 Share Consolidation - Stock Titan
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Major Shake-up: Investment Firm Leader Joins Amarin Board to Drive Shareholder Value - Stock Titan
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - markets.businessinsider.com
A Look at New Gold Inc (NGD) Shares in the Recent Past Indicates Growth - Sete News
Breakthrough: EPA Treatment Shows Double Impact on Heart Disease When Combined with Popular Diabetes Drug - Stock Titan
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
Assessing the Risk and Potential of Sempra’s (SRE) Stock - The News Heater
Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript - The Motley Fool
Amarin announce splan to initiate ratio change under ADR program - TipRanks
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - The Manila Times
Amarin Corp. (AMRN) Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing - StreetInsider.com
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - StockTitan
How Amarin's Latest European Reimbursement Victory Strengthens Its Cardiovascular Market Position - Stock Titan
Will Amarin's Q4 Earnings Mark a Turning Point? Key Date and Details Revealed - Stock Titan
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Amarin stock touches 52-week low at $0.45 amid challenges - Investing.com
Italy grants VAZKEPA reimbursement for heart risk - Investing.com
Amarin appoints new chief financial officer - Investing.com
Amarin stock plunges to 52-week low of $0.46 amid challenges - Investing.com
Amarin granted extension to meet Nasdaq listing standards - Investing.com
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Amarin to present new cardiovascular research at ESC Congress - Investing.com
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - 富途牛牛
Amarin's VAZKEPA gains reimbursement approval in Greece - Investing.com
Amarin Corp Adr (AMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.38%
자본화:
|
볼륨(24시간):